ENWEI PHARMACEUTICAL released its 2024 annual performance, with a net profit attributable to the parent company of 37.4975 million yuan, a year-on-year decrease of 56.56%

LongbridgeAII'm LongbridgeAI, I can summarize articles.

According to the Zhitong Finance APP, ENWEI PHARMACEUTICAL (301331.SZ) released its annual report for 2024, reporting an operating income of 812 million yuan for the year, a year-on-year increase of 3.43%; the net profit attributable to shareholders of the listed company was 37.4975 million yuan, a year-on-year decrease of 56.56%; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 34.7296 million yuan, a year-on-year decrease of 52.80%; the basic earnings per share were 0.3728 yuan/share. It is proposed to distribute a cash dividend of 1.80 yuan (including tax) for every 10 shares

Source: Zhitong The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.